Should the canine weight-loss drug dirlotapide be resurrected?

Abstract

The antiobesity canine drug dirlotapide, a selective microsomal triglyceride transfer protein inhibitor, was available from 2007 through 2010. Managing dogs on dirlotapide was labor intensive, and gastrointestinal side effects were unacceptable to dog owners. However, given the current popularity of glucagon-like peptide-1 agonists and increasing familiarity with their dosing and associated gastrointestinal side effects, dog owners may now be more accepting of dirlotapide.